Collaboration with The University of Iowa Produces a Novel Ebola Therapeutic Patent

A patent from SugarCone Biotech founder Paul D Rennert and collaborators from the University of Iowa has published. Entitled “ANTI-TIM-1 ANTIBODIES AND USES THEREOF” the patent describes the use of specific anti-TIM-1 antibodies to prevent infection by the Ebola and Marburg filoviruses. This seminal finding will lead to the development of prophylactic treatments for the prevention of Ebola and Marburg virus infection in “hot zone ” settings. The antibodies were developed at Biogen Idec.